NASDAQ:GDTC CytoMed Therapeutics Q4 2025 Earnings Report $1.21 +0.07 (+6.14%) As of 11:38 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast CytoMed Therapeutics EPS ResultsActual EPS-$0.06Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACytoMed Therapeutics Revenue ResultsActual Revenue$0.06 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACytoMed Therapeutics Announcement DetailsQuarterQ4 2025Date2/15/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile CytoMed Therapeutics Earnings HeadlinesCytoMed Therapeutics (NASDAQ:GDTC) Shares Up 6.5% - What's Next?June 13 at 2:59 AM | americanbankingnews.comCytoMed Therapeutics Shareholders Approve All Resolutions at May 22 AGMJune 3, 2026 | tipranks.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of the profits are typically already gone. SpaceX insiders bought in at a $20 billion valuation - you're being offered entry at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's supply chain, still priced like Wall Street hasn't noticed. It powers critical infrastructure Musk's operation can't run without. Dylan Jovine is naming it today, free.June 15 at 1:00 AM | Behind the Markets (Ad)CytoMed Renames Subsidiary to Drive Asian and International ExpansionMay 11, 2026 | tipranks.comCytoMed Therapeutics Sets May 22, 2026 AGM With Expanded Share-Issuance Mandate on the TableApril 14, 2026 | tipranks.comCytoMed Therapeutics Widens 2025 Loss as It Accelerates Cell Therapy Trials and Southeast Asia ExpansionMarch 31, 2026 | tipranks.comSee More CytoMed Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CytoMed Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytoMed Therapeutics and other key companies, straight to your email. Email Address About CytoMed TherapeuticsCytoMed Therapeutics (NASDAQ:GDTC), a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.View CytoMed Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationForget AI for a Moment, This Homebuilder Is Stealing the ShowWhy Oracle's 10% Drop May Be Telling the Wrong StorySpotify's "North Star" Outlook Was Music to Investors Ears Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
